Centre Hospitalier De Dieppe

The Intensive Care unit at Centre Hospitalier De Dieppe is conducting trials that address severe bacterial infections leading to sepsis and subsequent organ failure. One study evaluates high‑dose intravenous vitamin C to reduce mortality and persistent organ dysfunction, while another explores an adjunctive therapy for refractory shock.

• High‑dose vitamin C versus placebo in septic ARDS
• Adjunctive dexmedetomidine for refractory septic shock

These investigations aim to improve outcomes for critically ill patients with life‑threatening infections.

Research in the respiratory domain focuses on patients with acute respiratory distress syndrome (ARDS) secondary to infection. The trials test interventions that may shorten mechanical ventilation time and protect lung function, including antioxidant therapy and sedation strategies.

• Vitamin C impact on ventilator dependence
• Dexmedetomidine effect on respiratory support

By targeting lung injury, the studies seek to enhance recovery and reduce intensive care stay.

The site’s critical care program examines broader aspects of shock and organ support, encompassing both bacterial and undefined disease categories. Objectives include comparing mortality rates and the need for renal replacement or vasopressor support under novel treatment regimens.

• Composite endpoint of death or organ dysfunction
• 30‑day mortality with dexmedetomidine adjunct

Findings from these trials could inform best practices for managing severe systemic infections in ICU settings.